NCT05455619: Evexomostat Plus Alpelisib and Fulvestrant in Postmenopausal Women at Risk for Hyperglycemia With Breast Cancer

NCT05455619
Breast Cancer Type: HR+ & HER2-negative
Hormone Mutations: ER+, PR+
Other Mutations: PI3K
Breast Cancer Tissue: 
Recruitment Status: Not yet recruiting
Phase 1|Phase 2
Drug Category: Misc Inhibitor

Key Eligibility Criteria:

Gender: All
Age: 18 Years and older (Adult, Older Adult)
Location of Metastases: 
Additional Notes: Patient must have a tumor that expresses the PIK3CA mutation
Exclusions: Patients with inflammatory breast cancer; Patients with symptomatic, unstable, untreated brain metastases- see trial for details; Patients who have received prior PI3K/Akt/mTOR inhibitor (e.g. Piqray/alpelisib, Afinitor/everolimus) or fulvestrant treatment
https://ClinicalTrials.gov/show/NCT05455619

Comments are closed.

Up ↑